Merganser Biotech was founded by Brian MacDonald and Gene Merutka and is focused on the evaluation of novel hepcidin mimetic peptides for the treatment of beta thalassemia and other rare hematological and iron overload diseases. In 2013 the company obtained an exclusive worldwide license to patent rights for this technology from the Regents of the University of California.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/19/15 | $28,000,000 | Series A |
BioAdvance Frazier Healthcare Novartis Venture Funds Osage University Partners Stateside Developments Sutter Hill Ventures | undisclosed |
